Shell Asset Management Co. Buys 1,571 Shares of United Therapeutics Co. (NASDAQ:UTHR)

Shell Asset Management Co. increased its stake in shares of United Therapeutics Co. (NASDAQ:UTHR) by 81.8% during the 1st quarter, Holdings Channel.com reports. The firm owned 3,491 shares of the biotechnology company’s stock after acquiring an additional 1,571 shares during the quarter. Shell Asset Management Co.’s holdings in United Therapeutics were worth $802,000 at the end of the most recent reporting period.

Several other hedge funds have also modified their holdings of the stock. Dimensional Fund Advisors LP grew its stake in shares of United Therapeutics by 1.8% during the fourth quarter. Dimensional Fund Advisors LP now owns 561,950 shares of the biotechnology company’s stock valued at $123,566,000 after purchasing an additional 9,962 shares during the last quarter. LSV Asset Management grew its stake in shares of United Therapeutics by 40.3% during the first quarter. LSV Asset Management now owns 529,519 shares of the biotechnology company’s stock valued at $121,641,000 after purchasing an additional 152,151 shares during the last quarter. Norges Bank bought a new stake in shares of United Therapeutics during the fourth quarter valued at approximately $100,519,000. Charles Schwab Investment Management Inc. boosted its stake in United Therapeutics by 2.5% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 319,030 shares of the biotechnology company’s stock valued at $70,152,000 after acquiring an additional 7,723 shares during the last quarter. Finally, Nordea Investment Management AB boosted its stake in United Therapeutics by 677.6% in the first quarter. Nordea Investment Management AB now owns 300,920 shares of the biotechnology company’s stock valued at $72,422,000 after acquiring an additional 262,222 shares during the last quarter. 94.08% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

A number of equities analysts have issued reports on UTHR shares. Oppenheimer raised their price objective on shares of United Therapeutics from $375.00 to $400.00 and gave the company an “outperform” rating in a research note on Thursday, May 2nd. StockNews.com raised shares of United Therapeutics from a “buy” rating to a “strong-buy” rating in a research note on Monday, July 15th. JPMorgan Chase & Co. lifted their price target on shares of United Therapeutics from $280.00 to $300.00 and gave the stock an “overweight” rating in a research report on Tuesday, May 21st. Wells Fargo & Company lifted their price target on shares of United Therapeutics from $325.00 to $350.00 and gave the stock an “overweight” rating in a research report on Wednesday, June 12th. Finally, The Goldman Sachs Group lifted their price target on shares of United Therapeutics from $218.00 to $240.00 and gave the stock a “neutral” rating in a research report on Friday, May 3rd. Two research analysts have rated the stock with a hold rating, ten have issued a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $330.64.

United Therapeutics Trading Up 0.5 %

Shares of NASDAQ:UTHR opened at $338.22 on Friday. The company has a quick ratio of 3.64, a current ratio of 3.77 and a debt-to-equity ratio of 0.04. United Therapeutics Co. has a 12 month low of $208.62 and a 12 month high of $343.98. The company’s fifty day simple moving average is $303.01 and its 200 day simple moving average is $257.24. The firm has a market cap of $15.00 billion, a price-to-earnings ratio of 15.99, a PEG ratio of 1.47 and a beta of 0.55.

United Therapeutics (NASDAQ:UTHR) last issued its quarterly earnings results on Wednesday, May 1st. The biotechnology company reported $6.17 earnings per share (EPS) for the quarter, beating the consensus estimate of $5.63 by $0.54. The firm had revenue of $677.70 million for the quarter, compared to analyst estimates of $620.31 million. United Therapeutics had a net margin of 42.05% and a return on equity of 18.72%. The company’s revenue was up 33.7% compared to the same quarter last year. During the same period in the previous year, the business earned $4.86 EPS. As a group, research analysts forecast that United Therapeutics Co. will post 24.87 EPS for the current fiscal year.

Insider Transactions at United Therapeutics

In related news, Director Christopher Causey sold 2,240 shares of United Therapeutics stock in a transaction dated Friday, May 3rd. The shares were sold at an average price of $259.91, for a total transaction of $582,198.40. Following the completion of the sale, the director now owns 4,185 shares of the company’s stock, valued at approximately $1,087,723.35. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. In other United Therapeutics news, Director Nilda Mesa sold 266 shares of the stock in a transaction that occurred on Tuesday, June 25th. The shares were sold at an average price of $318.58, for a total transaction of $84,742.28. Following the transaction, the director now owns 5,107 shares in the company, valued at approximately $1,626,988.06. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Director Christopher Causey sold 2,240 shares of the stock in a transaction that occurred on Friday, May 3rd. The stock was sold at an average price of $259.91, for a total transaction of $582,198.40. Following the transaction, the director now owns 4,185 shares in the company, valued at approximately $1,087,723.35. The disclosure for this sale can be found here. Insiders have sold 100,884 shares of company stock worth $29,622,803 in the last ninety days. Insiders own 12.50% of the company’s stock.

United Therapeutics Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.